Protalix BioTherapeuticsCompany Review & Valuation

Tel-Aviv Stock Exchange
Latest Price
Market Capitalization

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinantShow more glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.Show less

HQ Location
Karmiel, Israel

Stock Price

Price data not available for Protalix BioTherapeutics.


Please login or create a free account to view the contents of this section.

Similar Companies

Ovoca Bio
KalVista Pharmaceuticals

back to top